Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

For more information
on BPDCN, click here



The Company
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and tumor bulk.
Clinical Trials
Cancer Stem Cells
Platform
Stemline Therapeutics has developed a Discovery Platform called StemScreen to identify novel compounds that target and kill CSCs.


News
&
Events
6/10/2016
SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at EHA
6/6/2016
Stemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference
6/4/2016
SL-401 Ph. 2 BPDCN Data Delivered in ASCO Oral Presentation; High Response Rates
Copyright 2016 - Stemline Therapeutics, Inc. All rights reserved
Stemline